For example, the synthetic lethal interaction between BRCA2 mutations and PARP inhibition in breast cancer cells has led to the clinical use of PARP inhibitors in breast cancer patients (Ashworth et al, 2011). This evidence concerns the gene BRCA2 and breast carcinoma.